Trial Updates

Phase II/III trial of troriluzole in spinocerebellar ataxia 7:29
Phase II/III trial of troriluzole in spinocerebellar ataxia
Melissa Beiner • 26 Apr 2021
Clinical significance of white matter hyperintensities in mTBI 3:25
Clinical significance of white matter hyperintensities in mTBI
Jack Tsao • 27 Apr 2021
The efficacy and safety of SEP-363856 for Parkinson’s disease psychosis 3:44
The efficacy and safety of SEP-363856 for Parkinson’s disease psychosis
Stuart Isaacson • 21 Apr 2021
Phase II study of lecanemab in early AD 1:31
Phase II study of lecanemab in early AD
Chad Swanson • 26 Apr 2021
The latest clinical trials in Huntington’s disease: valbenazine, targeting behavior, and novel DMTs 4:28
The latest clinical trials in Huntington’s disease: valbenazine, targeting behavior, and novel DMTs
Tiago Mestre • 26 Apr 2021
Randomized trial of FUS subthalamotomy for PD 4:10
Randomized trial of FUS subthalamotomy for PD
José Obeso et al. • 22 Apr 2021
REGAIN study and extension trial of eculizumab in myasthenia gravis 1:34
REGAIN study and extension trial of eculizumab in myasthenia gravis
James F. Howard Jr. • 7 Apr 2021
Mindfulness meditation vs. headache education for migraine treatment 5:21
Mindfulness meditation vs. headache education for migraine treatment
Rebecca E. Wells • 20 Apr 2021
Concomitant immunosuppressive therapy in gMG patients on the REGAIN extension study 1:02
Concomitant immunosuppressive therapy in gMG patients on the REGAIN extension study
James F. Howard Jr. • 7 Apr 2021
Open-label extension study of lecanemab in early Alzheimer’s disease 4:57
Open-label extension study of lecanemab in early Alzheimer’s disease
Chad Swanson • 26 Apr 2021
The impact of COVID-19 in the UK MS Register COVID-19 prospective cohort study 5:36
The impact of COVID-19 in the UK MS Register COVID-19 prospective cohort study
Afagh Garjani • 26 Apr 2021
INTREPID trial: device features and study design 5:06
INTREPID trial: device features and study design
Jerrold Vitek • 16 Apr 2021
Updates on the INTREPID trial: 4-year follow-up 5:11
Updates on the INTREPID trial: 4-year follow-up
Jerrold Vitek • 16 Apr 2021
ADAPT analysis: efgartigimod for generalized myasthenia gravis 4:59
ADAPT analysis: efgartigimod for generalized myasthenia gravis
James F. Howard Jr • 7 Apr 2021
STOP 301: non-oral INP104 for the acute treatment of migraine 1:34
STOP 301: non-oral INP104 for the acute treatment of migraine
Jessica Ailani • 18 Apr 2021
Atogepant meets all endpoints in the Phase III ADVANCE trial for episodic migraine prevention 3:02
Atogepant meets all endpoints in the Phase III ADVANCE trial for episodic migraine prevention
Jessica Ailani • 18 Apr 2021
The content of VJNeurology is intended for healthcare professionals